Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Indaptus Therapeutics, Inc. Director's Dealing 2023

May 30, 2023

35475_dirs_2023-05-30_b07ee4cc-ef6e-4fad-a872-02e9b921eac3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Indaptus Therapeutics, Inc. (INDP)
CIK: 0001857044
Period of Report: 2023-05-25

Reporting Person: MADDALUNA ANTHONY J (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-05-25 Stock Option (right to buy) $1.82 A 12500 Acquired 2033-05-25 Common Stock (12500) Direct

Footnotes

F1: The stock option vests and becomes exercisable on May 25, 2024.